Table 4.
Basal characteristics, echocardiographic results, and RV 2DSTE of group 1 subgroups at 20 weeks of receiving chemotherapy
| Group 1A (N = 90) (patients with normal RV strain) | Group 1B(N = 10) (patients with decreased RV strain) | P value | |
|---|---|---|---|
| Age, years | 11.56 ± 1.99 | 14.50 ± 0.52 | 0.001* |
| Male gender, n (%) | 45 (50.0%) | 5 (50.0%) | 1.000 |
| BSA, m2 | 1.38 ± 0.07 | 1.50 ± 0.01 | 0.001* |
| LVEDD, cm | 3.62 ± 0.30 | 3.60 ± 0.21 | 0.789 |
| LVESD, cm | 1.97 ± 0.57 | 1.75 ± 0.26 | 0.225 |
| LVEF, % | 64.13 ± 7.51 | 66.50 ± 1.58 | 0.325 |
| LVGLS, % | − 23.88 ± 0.86 | − 23.60 ± 1.22 | 0.340 |
| RVGLS, % | − 24.22 ± 0.89 | − 17.40 ± 1.26 | 0.001* |
| Apical RVS, % | − 24.90 ± 0.76 | − 16.40 ± 2.36 | 0.001* |
| Mid RVS, % | − 24.21 ± 0.64 | − 17.01 ± 1.15 | 0.001* |
| Basal RVS, % | − 24.61 ± 1.05 | − 18.20 ± 1.68 | 0.001* |
| Tapse, cm | 1.85 ± 0.14 | 1.67 ± 0.24 | 0.044* |
| FAC, % | 35.89 ± 0.88 | 35.10 ± 1.19 | 0.070 |
BSA body surface area; LVEDD left ventricular end diastolic dimension; LVESD left ventricular end systolic dimension; LVEF left ventricular ejection fraction; LVGLS left ventricular global longitudinal strain; RVGLS right ventricular global longitudinal strain; Apical, Mid and Basal RVS right ventricular strain; Tapse tricuspid annular plane systolic excursion; FAC fractional area change
* = means significant